StemCells Inc. (NASDAQ:STEM) shares saw unusually-strong trading volume on Tuesday . Approximately 40,482,948 shares changed hands during trading, an increase of 1,608% from the previous session’s volume of 2,370,223 shares.The stock last traded at $2.59 and had previously closed at $0.37.

A number of equities research analysts have weighed in on STEM shares. Maxim Group restated a “buy” rating and set a $36.00 price objective on shares of StemCells in a research note on Tuesday, April 19th. Rodman & Renshaw started coverage on StemCells in a research note on Wednesday, April 20th. They set a “buy” rating and a $18.00 price objective for the company. S&P Equity Research lowered their price objective on StemCells from $3.72 to $3.24 in a research note on Wednesday, April 27th. Finally, Zacks Investment Research lowered StemCells from a “buy” rating to a “hold” rating in a research note on Thursday, April 28th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $13.58.

The company has a 50-day moving average price of $0.45 and a 200-day moving average price of $2.25. The stock’s market cap is $30.43 million.

StemCells, Inc is engaged in the research, development, and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. The Company’s lead product development program is its CNS Program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.